Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1

British Journal of Cancer

Volumn 82, Issue 4, 2000, Pages 981-989

  Suminami, Y ^a,b   Nagashima, S ^a   Vujanovic, N L ^a   Hirabayashi, K ^b   Kato, H ^b   Whiteside, T L ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Protection from apoptosis; SCC Ag 1; Serpin; Tumour associated protein

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CASPASE 3; COMPLEMENTARY DNA; ETOPOSIDE; INTERLEUKIN 2; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR CELL;

EID: 0033981683     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1028     Document Type: Article

References (54)

1. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW and Yuan J (1996) Human ICE/CED-3 protease nomenclature [letter]. Cell 87: 171
2. Belin D, Wohlwend A, Schleuning WD, Kruithof EK and Vassalli JD (1989) Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J 8: 3287-3294
3. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
4. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwick JM (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966-1968
5. Danos O and Mulligan RC (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85: 6460-6464
6. Datta R, Kojima H, Banach D, Bump NJ, Talanian RV, Alnemri ES, Weichselbaum RR, Wong WW and Kufe DW (1997) Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem 272: 1965-1969
7. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ and van Muijen GN (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumour progression. Am J Pathol 144: 70-81
8. Desjardins LM and MacManus JP (1995) An adherent cell model to study different stages of apoptosis. Exp Cell Res 216: 380-387
9. Dickinson JL, Bates EJ, Ferrante A and Antalis TM (1995) Plasminogen activator inhibitor type 2 inhibits tumour necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 270: 27894-27904
10. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG and Aalders JG (1996) Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14: 111-118
11. Enari M, Hug H and Nagata S (1995) Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78-81
12. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. [Review]. Cell 78: 539-542
13. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG and Kramer MD (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427
14. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F and Bevilacqua G (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71: 1003-1007
15. Gan H, Newman GW and Remold HG (1995) Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. J Immunol 155: 1304-1315
16. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184
17. Hirabayashi H, Yasumura S, Lin WC, Amoseato A, Johnson JT, Herberman RB and Whiteside TL (1995) Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells. Arch Otolaryngol Head Neck Surg 121: 285-292
18. Hu Y, Benedict MA, Wu D, Inohara N and Nunez G (1998) Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 95: 4386-4391
19. Kato H (1992) Squamous cell carcinoma antigen. In: Serological Cancer Markers, Sell S (ed), pp. 437-451. Humana Press: Clifton
20. Kato H and Torigoe T (1977) Radioimmunoassay for tumour antigen of human cervical squamous cell carcinoma. Cancer 40: 1621-1628
21. Kato H, Miyauchi F, Morioka H, Fujino T and Torigoe T (1979) Tumor antigen of human cervical squamous cell carcinoma: correlation of circulating levels with disease progress. Cancer 43: 585-590
22. Kato H, Nagaya T and Torigoe T (1984) Heterogeneity of a tumour antigen TA-4 of squamous cell carcinoma in relation to its appearance in the circulation. Gann 75: 433-435
23. Mino N, Iio A and Hamamoto K (1988) Availability of tumour-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer 62: 730-734
24. Miyashita T and Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157
25. Nagashima S, Kashii Y, Reichert TE, Suminami Y, Suzuki T and Whiteside TL (1997) Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo. Int J Cancer 72: 174-183
26. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y and Takada A (1994) Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumour dissemination. Cancer 73: 1398-1405
27. Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T and Aozasa K (1997) Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54: 238-244
28. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett GH (1997) Induction of apoptosis in multidrug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39: 417-423
29. Nawata S, Tsunaga K, Numa F, Tanaka T, Nakamura K and Kato H (1995) Serine protease inhibitor activity of recombinant squamous cell carcinoma antigen towards chymotrypsin, as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis 16: 1027-1030
30. Nawata S, Nakamura K, Tanaka T, Numa F, Suminami Y, Tsunaga N, Kakegawa H, Katunuma N and Kato H (1997) Electrophoretic analysis of the 'cross-class' interaction between novel inhibitory serpin, squamous cell carcinoma antigen-1 and cysteine proteinases. Electrophoresis 18: 784-789
31. Numa F, Takeda O, Nakata M, Nawata S, Tsunaga N, Hirabayashi K, Suminami Y, Kato H and Hamanaka S (1996) Tumour necrosis factor-α stimulates the production of pquamous cell carcinoma antigen in normal squamous cells. Tumour Biol 17: 97-101
32. Ohashi T, Boggs S, Robbins P, Bahnson A, Patrene K, Wei FS, Wei JF, Li J, Lucht L, Fei Y & et al (1992) Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA 89: 11332-11336
33. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T & et al (1993) Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30-36
34. Ormerod MG, O'Neill CF, Robertson D and Harrap KR (1994) Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 211: 231-237
35. Pan G, O'Rourke K and Dixit VM (1998) Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem 273: 5841-5845
36. Potempa J, Korzus E and Travis J (1994) The serpin superfamily of proteinase inhibitors: structure, function, and regulation. [Review]. J Biol Chem 269: 15957-15960
37. Pross HF, Baines MG, Rubin P, Shragge P and Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumour target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51-63
38. Reed JC (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. [Review]. Curr Opin Oncol 7: 541-546
39. Reed JC (1997) Double identity for proteins of the Bcl-2 family. [Review]. Nature 387: 773-776
40. Scherrer A, Kruithof EK and Grob JP (1991) Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia 5: 479-486
41. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM and Silverman GA (1995) A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 92: 3147-3151
42. Suminami Y, Kishi F, Sekiguchi K and Kato H (1991) Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem Biophys Res Commun 181: 51-58
43. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A and Baba S (1992) Plasminogen activator system in human breast cancer. Int J Cancer 50: 345-348
44. Takeda A, Yamamoto T, Nakamura Y, Takahashi T and Hibino T (1995) Squamous cell carcinoma antigen is a potent inhibitor of cysteine proteinase cathepsin L. FEBS Lett 359: 78-80
45. Takeshima N, Nakamura K, Takeda O, Morioka, H, Tamura, H, Takasugi N and Kato H (1990) Individualization of the cutoff value for serum squamous-cell carcinoma antigen using a sensitive enzyme immunoassay. Tumour Biol 11: 167-172
46. Tewari M and Dixit VM (1995) Fas-and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 270: 3255-3260
47. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM (1995a) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 81: 801-809
48. Tewari M, Telford WG, Miller RA and Dixit VM (1995b) CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis. J Biol Chem 270: 22705-22708
49. Vujanovic NL, Rabinowich H, Lee YJ, Jost L, Herberman RB and Whiteside TL (1993) Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic. Cell Immunol 151: 133-157
50. Vujanovic NL, Nagashima S, Giorda R, Herberman RB and Whiteside TL (1995a) Multiple mechanisms of killing of tumour cell targets by IL-2-activated natural killer cells. In: Abstract Book of the 9th International Congress of Immunology (San Francisco, CA), pp. 486(2883)
51. Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB and Whiteside TL (1995b) Antitumour activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol 154: 281-289
52. Vujanovic NL, Nagashima S, Herberman RB and Whiteside TL (1996) Non-secretory apoptotic killing by human NK cells. J Immunol 157: 1117-1126
53. Yoshida A, Ueda T, Wano Y and Nakamura T (1993) DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 84: 566-573
54. Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, Gately M, Robbins PD and Lotze MT (1994) Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 5: 1493-1506